Hemoglobin-based blood substitutes and risk of myocardial infarction and death [2]

JAMA

Volumn 300, Issue 11, 2008, Pages 1295-1296

  Keipert, Peter E ^a   Olofsson, Christina ^b   Winslow, Robert M ^a  

^a SANGART INC   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DIASPIRIN CROSSLINKED HEMOGLOBIN; HEMOGLOBIN; HEMOSPAN; NITRIC OXIDE; POLYMERIZED HEMOGLOBIN; UNCLASSIFIED DRUG; BLOOD SUBSTITUTE;

BLOOD TRANSFUSION; DEATH; DRUG SAFETY; HEART INFARCTION; HUMAN; INCIDENCE; LETTER; ORTHOPEDIC SURGERY; PRIORITY JOURNAL; RISK ASSESSMENT; SIDE EFFECT; TREATMENT OUTCOME; BLOOD DONOR; DRUG UTILIZATION; NOTE; SOUTH AFRICA;

BLOOD DONORS; BLOOD SUBSTITUTES; DRUG UTILIZATION; HEMOGLOBINS; HUMANS; SOUTH AFRICA; MYOCARDIAL INFARCTION;

EID: 51949117668     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.300.11.1295-b     Document Type: Letter

References (3)

1. Natanson C, Kern SJ, Lurie P, Banks SM, Wolfe SM. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. JAMA. 2008;299(19):2304-2312.
2. Olofsson C, Ahl T, Johansson T, et al. A multicenter clinical study of the safety and activity of maleimide-polyethylene glycol-modified hemoglobin (Hemospan) in patients undergoing major orthopedic surgery. Anesthesiology. 2006;105(6):1153-1163.
3. Olofsson C, Nygårds EB, Ponzer S, et al. A randomized, single-blind, increasing dose safety trial of an oxygen-carrying plasma expander (Hemospan) administered to orthopedic surgery patients with spinal anesthesia. Transfus Med. 2008;18(1):28-29.